Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen for reducing lipoprotein apheresis in hyperlipoproteinemia(a)
2021-003059-41Phase 3Active
- Sponsor
- Novartis
- Start
- Apr 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperlipoproteinemia, cardiac morbidity and atherosclerotic disease comparing Pelacarsen with Placebo (2 arms). Primary endpoint: Rate of lipoprotein apheresis sessions performed over 52 weeks normalized to the weekly lipoprotein apheresis schedule. Started Apr 2022; status: active.
02
Drugs
pelacarsen
03
Conditions
hyperlipoproteinemiacardiac morbidityatherosclerotic disease
Beyond the preview
Go deeper on 2021-003059-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003059-41.